AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17606173
Drug: Studies without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Studies without concurrent economic evaluation
Trial: 9073140
Drug: Intraduodenal triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal triglyceride infusion under euglycemic conditions
Trial: 9073140
Drug: Intraduodenal triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal triglyceride infusion under hyperglycemic conditions
Trial: 9073140
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of hyperglycemia vs euglycemia during intraduodenal triglyceride infusion
Trial: 7526027
Drug: L-asparaginase (L-ASP)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase (L-ASP) added to consolidation therapy for average risk patients (MRG)
Trial: 7526027
Drug: G-CSF administered
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF administered in intervals between intensification elements for high risk patients (HRG)
Trial: 7526027
Drug: Initial response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial response to a 7-day exposure to prednisone and first intrathecal injection of MTX
Trial: 7526027
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of blasts in the bone marrow (BM) at day 15 of treatment
Trial: 7526027
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment protocol including 8-drug induction, consolidation, reinduction, and maintenance therapy
Trial: 3319643
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin infusion
Trial: 3319643
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin infusion
Trial: 23447373
Drug: Donepezil (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10mg daily for 3 months)
Trial: 19011227
Drug: 10-minute lymphatic
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-minute lymphatic treatment
Trial: 12824973
Drug: Oral contraceptive/clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive/clomiphene citrate
Trial: 1975324
Drug: Local instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local instillation of hyperosmolar glucose solution
Trial: 730416
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg)
Trial: 29812
Drug: Hydrochlorthiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorthiazide (50 mg)
Trial: 29812
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Amiloride and Hydrochlorthiazide (50 + 5 mg)
Trial: 28542805
Drug: Higher hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Higher hydrocortisone (HCT) dose (0.4-0.6 mg/kg body weight)
Trial: 28542805
Drug: Lower hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lower hydrocortisone (HCT) dose (0.2-0.3 mg/kg body weight)
Trial: 23524089
Drug: Diltiazem (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0 mg, 30 mg, 60 mg, 120 mg)
Trial: 23524089
Drug: Verapamil (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0 mg, 30 mg, 60 mg, 120 mg)
Trial: 23524089
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg) with naloxone
Trial: 23524089
Drug: Verapamil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (60 mg) with naloxone
Trial: 23524089
Drug: Verapamil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (60 mg)
Trial: 19592625
Drug: Albiglutide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide (30 mg weekly, 50 mg biweekly, 100 mg monthly)
Trial: 9766261
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 mcg) administered through continuous subcutaneous night infusion from midnight to 08:00 at increasing rate between 03:00 and 08:00 h
Trial: 9766261
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 mcg) administered through subcutaneous injections at 20:00, 22:00, and 24:00 h
Trial: 7828258
Drug: Oral ephedrine
RxNorm normalized name: ephedrine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ephedrine 30 mg, orally, 30 min before subarachnoid block
Trial: 3046593
Drug: Combined non‐specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined non‐specific and specific immunotherapy (BCG and neuraminidase‐treated autologous tumour cells) over a 2 year programme
Trial: 28300812
Drug: naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G)
Trial: 26525620
Drug: naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone 50 mg/day + guanfacine placebo (N+GP)
Trial: 26525620
Drug: naltrexone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone placebo + guanfacine (NP+G)
Trial: 19132200
Drug: Heparin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin prophylaxis prior to enrollment
Trial: 15159320
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day UDCA for 21 days
Trial: 15159320
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day UDCA for 21 days
Trial: 15159320
Drug: 900 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/day UDCA for 21 days
Trial: 9572636
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (1 cc s.c.)
Trial: 8147095
Drug: Purified hemagglutinin
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified hemagglutinin antigen (HA) 7.5 micrograms/0.25 ml
Trial: 8147095
Drug: Purified hemagglutinin
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified hemagglutinin antigen (HA) 22.5 micrograms/0.25 ml
Trial: 8147095
Drug: Purified hemagglutinin
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified hemagglutinin antigen (HA) 67.5 micrograms/0.25 ml
Trial: 8147095
Drug: Standard split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard split product vaccine (ST) 22.5 micrograms/ml
Trial: 8147095
Drug: Purified hemagglutinin
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified hemagglutinin antigen (HA) highest dose
Trial: 8147095
Drug: Equivalent dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent dose of HA vaccine
Trial: 29329957
Drug: SAB-301 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAB-301 (1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 50 mg/kg)
Trial: 29329957
Drug: SAB-301 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAB-301 (50 mg/kg)
Trial: 26149465
Drug: EA 40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA 40,000 U subcutaneously once weekly
Trial: 26149465
Drug: DA 500
RxNorm normalized name: Xeloda 500mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA 500 mcg every 3 weeks
Trial: 23880655
Drug: Sugar-free Red
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free Red Bull (SF-RB) containing caffeine (160 mg) and taurine (2000 mg)
Trial: 23880655
Drug: Caffeine only
RxNorm normalized name: Caffeine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine only drink (160 mg)
Trial: 20608874
Drug: HIV-1 gp120
RxNorm normalized name: HIV-1 gp120 Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 gp120 vaccine
Trial: 12780402
Drug: Timolol maleate/latanoprost
RxNorm normalized name: timolol maleate/latanoprost/PF 0.5 %-0.005 % OPHTHALMIC DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol maleate/latanoprost fixed combination (TLFC) given once each evening
Trial: 12780402
Drug: Brimonidine and
RxNorm normalized name: brimonidine and ripasudil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine and timolol solution given twice daily
Trial: 9359537
Drug: Catheter-based revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-based revascularization and conventional care (including lipid-lowering therapy if prescribed)
Trial: 8239105
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization of albuterol (10 mg nebulized in 70 mL over two hours)
Trial: 8239105
Drug: Intermittent nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulization of albuterol (2.5 mg at 30, 60, 90, and 120 minutes after initial treatment)
Trial: 4027764
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly before anaesthesia (neonates)
Trial: 4027764
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg X kg‐1 of alpha‐tocopheryl acetate orally for three days before anaesthesia (Group 2 infants)
Trial: 4027764
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly three hours before anaesthesia (Group 3 infants)
Trial: 29865227
Drug: Ferulic acid
RxNorm normalized name: Ferulic acid
DrugBank: Ferulic acid (DB07767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferulic acid (1000 mg daily)
Trial: 26566754
Drug: Oral pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pregabalin 300 mg
Trial: 24836866
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every month for the first 3 months, followed by every 2 months
Trial: 22349989
Drug: RVX-208 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX-208 100 mg bid for 24 weeks
Trial: 22349989
Drug: RVX-208 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX-208 100 mg bid for 26 weeks
Trial: 18657831
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% phenylephrine drops
Trial: 14671144
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (low dose: 30 mU/m2.min, high dose: 200 mU/m2.min) during recombinant human FSH (r-hFSH) administration
Trial: 14671144
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/d) treatment for 5 months
Trial: 14671144
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment with high-dose insulin infusion
Trial: 7916925
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg OKT3
Trial: 1453598
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg or 10 mg OKT3
Trial: 7916925
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg OKT3
Trial: 3841206
Drug: Diflunisal 1000
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflunisal 1000 mg once daily for 14 days
Trial: 3841206
Drug: Diflunisal 500
RxNorm normalized name: diflunisal 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 500 mg twice daily for 14 days
Trial: 30959740
Drug: Synergy 1
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergy 1 (10 g per day)
Trial: 30266885
Drug: Thrombolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis treatment in infratentorial AIS with baseline NIHSS score > 6
Trial: 27143684
Drug: Outpatient intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient intensification of HF therapy
Trial: 25585779
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) cream
Trial: 3759280
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day metoprolol
Trial: 18037099
Drug: C.E.R.A. (methoxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. (methoxy polyethylene glycol-epoetin beta) administered intravenously once every 2 weeks
Trial: 18037099
Drug: Epoetin administered
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin administered 3 times weekly
Trial: 16039618
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) with antidepressant medication (n = 17)
Trial: 16039618
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication alone (n = 23)
Trial: 11237351
Drug: 0.4% CMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% CMP solution
Trial: 11237351
Drug: 2.0% CMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% CMP solution
Trial: 11237351
Drug: Water containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water containing colorant and clouding agent
Trial: 8297216
Drug: DMT 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT 0.05 mg/kg
Trial: 8297216
Drug: DMT 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT 0.1 mg/kg
Trial: 8297216
Drug: DMT 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT 0.2 mg/kg
Trial: 8297216
Drug: DMT 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT 0.4 mg/kg
Trial: 8297216
Drug: DMT (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT (all doses)
Trial: 3671137
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml (5 mg) nebulized metaproterenol
Trial: 3671137
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml nebulized metaproterenol
Trial: 3671137
Drug: 0.3 ml
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml nebulized metaproterenol
Trial: 3671137
Drug: 0.0 ml
RxNorm normalized name: ALCOHOL 6.3 mL in 10.0 mL TOPICAL SPRAY [Sanell Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 ml (placebo)
Trial: 27446836
Drug: Split-dose PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose PEG lavage
Trial: 27446836
Drug: Single 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 4 L PEG lavage
Trial: 23809044
Drug: Increased urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urine cotinine (≥ 30 ng/mg creatinine)
Trial: 21368757
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of gemfibrozil taken 0 hours before repaglinide
Trial: 21368757
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of gemfibrozil taken 1 hour before repaglinide
Trial: 21368757
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of gemfibrozil taken 3 hours before repaglinide
Trial: 21368757
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of gemfibrozil taken 6 hours before repaglinide
Trial: 21368757
Drug: Control: 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: 0.25 mg of repaglinide alone
Trial: 19500860
Drug: Topical levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levobupivacaine (5 ml, 25 mg/10 ml)
Trial: 19500860
Drug: Saline swabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline swabs (5 ml)
Trial: 19500860
Drug: Topical levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levobupivacaine and saline swabs
Trial: 8356895
Drug: Psychiatric day
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric day treatment
Trial: 29781308
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone injection
Trial: 28061430
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (once-daily)
Trial: 25315404
Drug: Delayed-release DMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release DMF 240 mg PO BID
Trial: 25315404
Drug: Delayed-release DMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release DMF 240 mg PO TID
Trial: 17924779
Drug: Progesterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (100 mg to 300 mg twice daily for 9 weeks)
Trial: 8630638
Drug: Intramuscular meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular meloxicam 15 mg for 7 days
Trial: 8630638
Drug: Intramuscular piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular piroxicam 20 mg for 7 days
Trial: 8630638
Drug: Intramuscular meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular meloxicam 15 mg
Trial: 6391588
Drug: No behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No behavioural treatment
Trial: 30530801
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg (single agent)
Trial: 30530801
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg plus rituximab 375 mg/m2
Trial: 17174705
Drug: Constant infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant infusion of 1 g pralidoxime over 1 hour every hour for 48 hours after a 2 g loading dose
Trial: 17174705
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of 1 g pralidoxime over 1 hour every 4 hours for 48 hours after a 2 g loading dose
Trial: 14577980
Drug: 4-mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg nicotine polacrilex lozenge
Trial: 14577980
Drug: 2-mg nicotine
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg nicotine polacrilex lozenge
Trial: 14577980
Drug: Lozenges administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenges administered every 90 min
Trial: 14577980
Drug: 4-mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg nicotine polacrilex lozenge (used as directed)
Trial: 10761819
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (multiple doses over 14 days)
Trial: 1534646
Drug: SP (morphine‐scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP (morphine‐scopolamine + pancuronium)
Trial: 1534646
Drug: SV (morphine‐scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SV (morphine‐scopolamine + vecuronium)
Trial: 6374246
Drug: Intravenous instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous instillation of sodium nitroprusside (39 patients)
Trial: 6374246
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (17 patients)
Trial: 22952580
Drug: 8 days
RxNorm normalized name: rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 days of antibiotic treatment
Trial: 22952580
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days of antibiotic treatment
Trial: 17386350
Drug: telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 80 mg/amlodipine 2.5 mg daily
Trial: 17386350
Drug: telmisartan 120
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 120 mg/amlodipine 2.5 mg daily